Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Document › Details

Proteros Biostructures GmbH. (11/22/16). "Press Release: Proteros Signs Second Oncology Collaboration with MSD on Epigenetic Target". Martinsried.

Organisations Organisation Proteros Biostructures GmbH
  Group Proteros (Group)
  Organisation 2 Merck, Sharp & Dohme
  Group Merck (US) (MSD) (Group)
Products Product drug discovery
  Product 2 small-molecule cancer drug
Index term Index term Merck (US)–Proteros: drug discovery services, 201611– collab €na upfront + research funding + $167m milestones + royalties r+d small mol cancer drug
Persons Person Neuefeind, Torsten (Proteros Biostructures 200610 Managing Director)
  Person 2 Arnold, Katja (MC Services 201309 CIRO Executive Director before Wilex AG + CAT Consultants)

Proteros to receive upfront and research funding plus milestone payments of up to $167 million plus tiered royalties

Proteros biostructures GmbH today announced that the company has entered into a second research agreement with Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA (known as MSD outside the US and Canada). The new collaboration is aimed at developing small molecule compounds against an additional epigenetic target for the potential treatment of various cancers.

Under the terms of the agreement, Proteros receives an upfront payment and research funding and will be eligible to receive development, regulatory and commercial milestone payments up to $167 million plus tiered royalties. Additional details of the collaboration were not disclosed.

Dr. Torsten Neuefeind, CEO of Proteros commented: “We are pleased to expand our relationship with MSD just one year after starting our first collaboration in epigenetic drug discovery. This new collaboration will benefit from our previous and ongoing work with the team at MSD and we look forward to a further successful partnership, which potentially could transform the treatment of many cancers.”

About epigenetics and Proteros’ expertise in epigenetics:

Epigenetics (“outside of genetic”) addresses a novel paradigm in the organization of genetic information and covers a broad class of enzymes and hundreds of potential drug targets. Epigenetic changes - unlike genetic alterations - provide the potential to reverse disease processes. Reversing those changes with epigenetic drugs is a fundamentally new opportunity in drug discovery. Proteros’ proprietary nucleosomal epigenetic assay technologies (NEAT) and the structure guided discovery platform allow the opening of gateways to address epigenetic mechanisms for new medicines.

About Proteros biostructures

Proteros, Martinsried/Munich, is a Germany-based, private biotech company focused on drug discovery for novel and technically demanding targets. One particular focus is on epigenetic targets. The company is today working for most of the largest pharmaceutical and biotech companies in Europe, US and Japan in collaborative relationships and has further built a pipeline of partnered and proprietary discovery projects with a strong focus on epigenetic targets. Co-founded by Nobel Laureate Prof. Robert Huber, Proteros has a strong heritage in structural biology and provides one of the largest and most powerful platforms for structure guided drug discovery. Epigenetic targets are predicted to become one of the fastest growing target classes in Pharma within the next 10 years. More information can be found at

Proteros Contacts:

For Press enquiries:

Dr. Torsten Neuefeind, CEO
Proteros biostructures GmbH

Katja Arnold, MC Services AG
Phone: +49 89 210 228-0

Record changed: 2017-01-17


Picture [LSA] – The Business Web Portal 650x89px

More documents for Proteros (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

» top